Emergent BioSolutions (EBS) Non-Current Deferred Tax Liability (2013 - 2026)

At the end of FY2025, Emergent BioSolutions' Non-Current Deferred Tax Liability came in at $37.8 million, down 9.4% from FY2024.

• Annual Non-Current Deferred Tax Liability has declined for four consecutive years, with a five-year compound annual growth rate of -6.6% (FY2020 to FY2025).
• In prior years, Emergent BioSolutions' Non-Current Deferred Tax Liability was $41.7 million in FY2024 (-11.7%), $47.2 million in FY2023 (-20.9%), $59.7 million in FY2022 (-36.0%) and $93.3 million in FY2021 (+75.4%).
• Quarterly Non-Current Deferred Tax Liability has run from a low of $33.3 million in Q1 2026 to a high of $113.9 million in Q3 2022 over five years.
• On a year-over-year basis, Non-Current Deferred Tax Liability has declined in each of the last four quarters, with an average decline of 2.0% over the last eight quarters.
• The strongest year-over-year quarter for Non-Current Deferred Tax Liability in the past five years was Q3 2022, with growth of 114.9%; the weakest was Q3 2023, with a decline of 54.0%.
• According to Business Quant data, Non-Current Deferred Tax Liability for the three prior quarters was $33.3 million (Q1 2026), $37.8 million (Q4 2025) and $36.3 million (Q3 2025).